By Nigam Arora
On October 17th, our paid members were alerted that a major development on weight loss drug pricing was likely coming and that it could significantly impact Eli Lilly (LLY) stock.
Yesterday, there was a signal in ZYX Buy on a key development that could materially impact LLY stock.
Eli Lilly, one of the stocks in the ZYX Buy Core Model Portfolio by The Arora Report, has struck a deal with President Trump’s administration to lower the price of its weight loss drugs. Reduced pricing and expanded access, particularly through Medicare and Medicaid, are expected to drive significantly wider adoption of Lilly’s GLP-1/obesity treatments. Increased usage often offsets lower price points, and the stock is reflecting this dynamic.
LLY is long from $318.45, and as of this writing, it is trading at $1030.39 as of this writing, representing a gain of 224%. With this expanded market opportunity, there is now a high probability of LLY becoming the first $1 trillion pharmaceutical company.
The new target zone is $1556 – $1578.
What To Do Now
- Those already in LLY stock may consider continuing to hold.
- Those not in LLY stock may consider waiting for a new buy zone, which will be in ZYX Buy. Please click here to start a 30 day free trial to ZYX Buy.
Previous Signal
Below is an excerpt from the October 17 signal that alerted paid members weeks in advance. There are very nice profits on LLY. LLY is trading at $799.15 as of this writing.
President Trump wants to reduce weight-loss drug prices. Weight-loss pills are ahead from LLY. If LLY is allowed to charge prices similar to injectables, LLY stock may stage a leg up. However, President Trump appears to want to bring the price of weight-loss injectables down to $150 per month. If President Trump is successful, LLY stock could fall from here.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
These posts were published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 1% of the content from our paid services. …TO RECEIVE REMAINING 99%, INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES AND SIGNALS IN REAL TIME, TAKE A FREE
TRIAL TO PAID SERVICES.
The Arora Report is one of the only major global investment newsletters that does not employ a single salesperson—because it does not need to. While competitors rely on high-pressure sales tactics, The Arora Report grows purely through results, with satisfied members recommending it to their family and friends.
Join the service that investors trust the most and recommend to family and friends.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
